IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 926-950 out of 1281.

<< < 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 > >>

Public Release: 30-Sep-2015
Nature
Experimental cancer drug shows therapeutic promise in mouse models of multiple sclerosis
An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain and basal cell cancers improves the symptoms of mice with a form of the debilitating neurological disorder multiple sclerosis (MS), according to new research from NYU Langone Medical Center.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 30-Sep-2015
EMBO Reports
Scientists discover how to trap cancer cells before they spread
Researchers at the University of Copenhagen and the Francis Crick Institute have discovered a new way to potentially 'fence in' a tumor and help stop cancer cells spreading, according to a study printed in EMBO Reports on Oct. 1 2015.
Novo Nordisk Foundation, Cancer Research UK, FEBS, Danish Cancer Society, Danish Council for Independent Research, Innovation Fund Denmark, Wellcome-Trust

Contact: Janine Erler
janine.erler@bric.ku.dk
45-20-34-11-06
University of Copenhagen, Biotech Research & Innovation Centre

Public Release: 30-Sep-2015
Journal of Molecular Diagnostics
Study lays groundwork for blood test to aid in the detection and monitoring of myeloma
Only 5 percent of myeloma cases are stage I when diagnosed. One reason may be the lack of good routine screening tests to identify patients who will progress to myeloma. A new study in The Journal of Molecular Diagnostics found that abnormal levels of microRNAs (miRNAs) detected in the bone marrow of multiple myeloma patients may also be detectable in peripheral blood, and their measurement may be a way to both mark myeloma onset and track its progression from earlier asymptomatic stages.
NIH/Intramural Research Program, NIH/National Cancer Institute

Contact: Eileen Leahy
jmdmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 30-Sep-2015
Nature
'Avatars' reveal new genetic sources of drug response in late-stage colorectal therapy
Using pieces of human tumors grafted into mice, a team led by Johns Hopkins Kimmel Cancer Center researchers and their colleagues from the University of Torino has identified new mutations in six genes related to drug resistance and sensitivity in late-stage colorectal cancer.

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 30-Sep-2015
EMBO Reports
Scientists discover how to trap cancer cells before they spread
Researchers at the Francis Crick Institute and the University of Copenhagen have discovered a new way to potentially 'fence in' a tumor and help stop cancer cells spreading.
Cancer Research UK, FEBS, Novo Nordisk Foundation, Danish Cancer Society, Danish Council for Independent Research, Innovation Fund Denmark and Wellcome Trust

Contact: Press Office
020-346-98300
Cancer Research UK

Public Release: 30-Sep-2015
European Society for Paediatric Endocrinology Annual Meeting
Scientists create insulin-producing cells that may treat diabetes
A new technique to produce cells with insulin-secretion capabilities has been developed, according to research presented today at the 54th Annual European Society for Paediatric Endocrinology Meeting. The technique could be further developed to be used in the transplantation for patients with type 1 diabetes.

Contact: Fiona Docherty
fiona.docherty@bioscientifica.com
44-014-546-42252
BioScientifica Limited

Public Release: 30-Sep-2015
Genome Research
Researchers show that genetic background regulates tumor differences
Researchers from Uppsala University, Sweden, and the Broad Institute, USA, have identified both similarities and differences between a single tumor type in multiple dogs breeds; a finding they believe parallels the situation in the cancer of human patients.

Contact: Ingegerd Elvers
ielvers@broadinstitute.org
46-737-349-875
Uppsala University

Public Release: 29-Sep-2015
Journal of Clinical Pathology
Intratumor morphological heterogeneity of cancer is not related to chromosome aberrations
Intratumor morphological heterogeneity (diversity) of breast cancer is not related to chromosome aberrations. This conclusion was made based on the study of one case with aggressive variant of breast cancer -- invasive micropapillary carcinoma by researchers from Tomsk State University, Tomsk Cancer Research Institute, and Institute of Medical Genetics.

Contact: Tatiana Arsenyeva
iro2@mail.tsu.ru
National Research Tomsk State University

Public Release: 29-Sep-2015
Radiology
MRI technique could reduce need for breast biopsies
A magnetic resonance breast imaging technique that uses no ionizing radiation or contrast agent could reduce unnecessary biopsies by providing additional information about suspicious findings on X-ray screening mammography, according to a new study.

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America

Public Release: 29-Sep-2015
Advanced Materials
Researchers disguise drugs as platelets to target cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work was tested successfully in an animal model.
National Institutes of Health

Contact: Matt Shipman
matt_shipman@ncsu.edu
919-515-6386
North Carolina State University

Public Release: 29-Sep-2015
Biofabrication
Scientists pioneer 3-D-printed drug delivering micro-needles
Researchers have developed a new technique to produce a 3-D 'micro-printed' array of needles capable of drug delivery. The technique would offer a pain-free drug delivery device that would allow drugs to diffuse within the body as the biomaterial device degrades in the body. This offers treatments for a wide range of diseases, including melanoma cancers. The results are published Sept. 30 in the journal Biofabrication.

Contact: Steve Pritchard
steve.pritchard@iop.org
44-117-930-1032
IOP Publishing

Public Release: 29-Sep-2015
International Journal of Medical Engineering and Informatics
Risk factors for prostate cancer
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk. In contrast, obesity, alcohol abuse, and smoking show a negative association with the disease. Details are reported in the International Journal of Medical Engineering and Informatics.

Contact: Albert Ang
press@inderscience.com
Inderscience Publishers

Public Release: 29-Sep-2015
Population Health Management
Underdetection, not overdiagnosis, is the real problem in breast cancer screening
While screening mammography has a well-established history of reducing death from breast cancer and enabling earlier detection of breast disease, questions regarding overtreatment and overdiagnosis have entered the screening debate. A new review article discusses the topics of overdiagnosis and overtreatment and the role of providers and technology to address the issues in the context of population health. The article appears in a new supplement to Population Health Management.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 29-Sep-2015
Journal of Environmental Health
Arsenic found in many US red wines, but health risks depend on total diet
A new UW study that tested 65 wines from America's top four wine-producing states -- California, Washington, New York and Oregon -- found all but one have arsenic levels that exceed US drinking water standards. But health risks from that naturally-occurring toxic element depend on how many other high-arsenic foods and beverages, such as apple juice, rice, or cereal bars, an individual person eats.

Contact: Jennifer Langston
jlangst@uw.edu
206-543-2580
University of Washington

Public Release: 29-Sep-2015
Nano Letters
Sniffing out cancer with improved 'electronic nose' sensors
Scientists have been exploring new ways to 'smell' signs of cancer by analyzing what's in patients' breath. In ACS' journal Nano Letters, one team now reports new progress toward this goal. The researchers have developed a small array of flexible sensors, which accurately detect compounds in breath samples that are specific to ovarian cancer.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 29-Sep-2015
Trends in Cancer
Eight big questions in cancer research
Leading cancer researchers address eight of the 'big questions' facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 28-Sep-2015
New England Journal of Medicine
Multi-gene test enables some breast cancer patients to safely avoid chemotherapy
A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
NIH/National Cancer Institute

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Public Release: 28-Sep-2015
Scientific Reports
Scientists use microchip approach to visualize human breast cancer proteins
Virginia Tech Carilion Research Institute scientists present a new molecular toolkit to investigate protein assemblies natively formed in the context of human disease. BRCA1 gene regulatory complexes from cancer cells were visualized for the first time.

Contact: Paula Brewer Byron
paulabyron@vt.edu
540-526-2027
Virginia Tech

Public Release: 28-Sep-2015
European Cancer Congress (ECC2015)
Kolltan Pharmaceuticals announces KTN0158 preclinical data at ESMO 2015
Substantial shrinkage in tumors and favorable results from nonclinical toxicology studies support IND filing in 2015. Initiation of Phase 1 clinical trial in GIST and other KIT-dependent solid tumors anticipated in 2016.
Kolltan Pharmaceuticals

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Kolltan Pharmaceuticals, Inc.

Public Release: 28-Sep-2015
European Cancer Congress (ECC2015)
New England Journal of Medicine
New England Journal of Medicine publishes initial data from TAILORx breast cancer trial
Initial results announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a prospectively conducted global trial in 10,000+ women with early stage breast cancer, found that 1,626 trial participants with low Oncotype DX® Recurrence Score® results (≤ 10) who got hormonal therapy alone without chemotherapy had <1 percent chance of distant recurrence at five years, providing evidence that women in the future may effectively forego chemotherapy if their Recurrence Score is ≤10.
NIH/National Cancer Institute

Contact: ECOG-ACRIN Office of Communications
communications@ecog-acrin.org
215-789-3631
ECOG-ACRIN Cancer Research Group

Public Release: 28-Sep-2015
New England Journal of Medicine
Immunotherapy superior to chemotherapy for lung cancer in trial involving UTSW
An international team of cancer researchers that included UT Southwestern Medical Center physicians announced 'game-changing results' using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.
Bristol-Myers Squibb

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 28-Sep-2015
Proceedings of the National Academy of Sciences
Scientists decode structure at root of muscular disease
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating nemaline myopathy, a neuromuscular disease that causes muscle weakness.
National Institutes of Health, Welch Foundation

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 28-Sep-2015
European Cancer Congress 2015
New England Journal of Medicine
New drug improves outcome in treatment resistant kidney cancer
A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.
Exelixis, Inc.

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 28-Sep-2015
PLOS ONE
Early exposure to tobacco as a cause of behavioral problems in children
Researchers from Inserm and Pierre and Marie Curie University, in collaboration with the university hospitals of six French cities, have analyzed data on pre- and postnatal exposure to tobacco in the homes of 5,200 primary school children.

Contact: Isabella Annesi-Maesano
isabella.annesi-maesano@inserm.fr
INSERM (Institut national de la santé et de la recherche médicale)

Public Release: 28-Sep-2015
Journal of Clinical Oncology
HRT safe and perhaps beneficial in women treated for ovarian cancer, major trial shows
Women with the commonest type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival, a long-term clinical trial reports. The 24-year, phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer -- which accounts for 80-90 per cent of cases -- can safely take HRT during or after their treatment.
The Institute of Cancer Research London, Cancer Research UK

Contact: Henry French
henry.french@icr.ac.uk
020-715-35582
Institute of Cancer Research

Showing releases 926-950 out of 1281.

<< < 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!